SEC Form 10-Q filed by Olema Pharmaceuticals Inc.
$OLMA
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/2/2024 | $24.00 | Buy | Goldman |
| 1/30/2024 | $20.00 | Buy | Citigroup |
| 7/21/2023 | $21.00 | Outperform | Oppenheimer |
| 5/5/2023 | $16.00 | Overweight | CapitalOne |
| 2/22/2023 | $12.00 | Outperform | Credit Suisse |
| 7/6/2022 | $16.00 | Buy | Canaccord Genuity |
| 6/9/2022 | $12.00 | Neutral → Buy | H.C. Wainwright |
| 2/28/2022 | Neutral | HC Wainwright & Co. |
Goldman initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $24.00
Citigroup initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $20.00
Oppenheimer initiated coverage of Olema Pharmaceuticals with a rating of Outperform and set a new price target of $21.00
8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
SCHEDULE 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
10-Q - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4/A - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)